Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
Completed
Sunovion
Phase 3
2005-10-01
To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a
period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)
Completed
Sunovion
Phase 4
2006-12-01
The purpose of this study is to evaluate and compare the efficacy of arformoterol twice a day
and tiotropium once a day (dosed sequentially) versus tiotropium once a day alone in subjects
with Chronic Obstructive Pulmonary Disease (COPD).
Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD
Completed
Sunovion
Phase 4
2007-11-01
To evaluate the efficacy and safety of arformoterol tartrate inhalation solution 30μg/4mL QD
(two 15μg/2mL dosed in combination) over a 24-hour period compared to arformoterol tartrate
inhalation solution 15μg/2 mL BID in subjects with COPD.
Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Completed
Sunovion
Phase 2
2005-04-01
The purpose of this study is to compare the blood levels of arformoterol tartrate inhalation
solution to racemic formoterol in male and female subjects with mild to moderate Chronic
Obstructive Pulmonary Disease (COPD).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
